(Q46826559)

25 December 2017

title

Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans (English)

1 reference

25 December 2017

1 reference

Y Yamasaki

1

1 reference

25 December 2017

I Ieiri

2

1 reference

25 December 2017

H Kusuhara

3

1 reference

25 December 2017

T Sasaki

4

1 reference

25 December 2017

M Kimura

5

1 reference

25 December 2017

H Tabuchi

6

1 reference

25 December 2017

Y Ando

7

1 reference

25 December 2017

S Irie

8

1 reference

25 December 2017

Ja Ware

9

1 reference

25 December 2017

Y Nakai

10

1 reference

25 December 2017

S Higuchi

11

1 reference

25 December 2017

Y Sugiyama

12

1 reference

25 December 2017

language of work or name

English

0 references

publication date

2 January 2008

1 reference

25 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

25 December 2017

volume

84

1 reference

25 December 2017

page(s)

95-103

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

Azo reduction of sulphasalazine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

Drug therapy: Sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Which component of sulphasalazine is active in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Clinical Pharmacokinetics of Sulphasalazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Mapping AAC1 AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Effect of ABCG2 genotype on the oral bioavailability of topotecan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Functional analysis of SNPs variants of BCRP/ABCG2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100459

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100459

1 reference

25 December 2017

PubMed ID

18167504

1 reference

25 December 2017